Journal: Molecular Therapy. Methods & Clinical Development
Article Title: CAR T cell engineering impacts antigen-independent activation and co-inhibition
doi: 10.1016/j.omtm.2025.101586
Figure Lengend Snippet: Expression patterns of activation and co-inhibition markers in healthy-donor- and CLL-patient-derived CAR T cells by flow cytometry (A) CD69 surface expression in either scFv + ,CD4 + or scFv + ,CD8 + CAR T cells over the course of 4 weeks. Bars represent the mean ± SD; each data point represents an individual donor. Statistics: two-sided t test between LV or SB samples from days 9 and 30. (B) Representative flow cytometry image of target epitope expression in K562 and NALM-6-R110 cells. (C) Pooled results of in vitro co-culture assays indicating the killing of CD19 + , IGLV3-21 R110+ NALM-6-R110 target cells in relation to CD19 − ,IGLV3-21 R110 K562 non-target cells. Bars represent the mean ± SD of pooled experiments. E:T ratios are indicated as symbol color and source donor as symbol shape. (D) Histogram of the PD-1, TIM-3, and LAG-3 expression in CD3 + T cells (HD175) on day 9. (E) Visualization of the CD4, CD8, PD-1, and LAG-3 distribution pattern of CD3 + T cells (HD175) on day 16. Technical duplicate measurements were concatenated and tSNE analysis performed with standard settings.
Article Snippet: Immediately after combining target and effector cells, half of each well was subjected to flow cytometric analysis and the other half incubated for 24 h. Killing of target cells was assessed by gating for viable (DAPI-negative, #130-111-570, Miltenyi Biotec) CD3 − ,CD19 + ,R110 + target NALM-6-R110 cells and by normalizing their percentage after 24-h incubation to 0-h incubation time.
Techniques: Expressing, Activation Assay, Inhibition, Derivative Assay, Flow Cytometry, In Vitro, Co-Culture Assay